In conclusion, these data indicate that PARP inhibitors exert a powerful selective pressure for BRCA reversion mutations in BRCA-mutant tumors, as evidenced by extensive convergent evolution in a patient with BRCA2-mutant prostate cancer. This evidence concerns the gene BRCA2 and prostate carcinoma.